Scinai Immunotherapeutics Ltd
SCNI1.525USD
+0.055+3.74%
Market hours （ET）Quotes delayed by 15 min
1.30MMarket Cap
0.35P/E TTM
More Details of Scinai Immunotherapeutics Ltd Company
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Company Info
Ticker SymbolSCNI
Company nameScinai Immunotherapeutics Ltd
IPO dateJun 07, 2007
CEOMr. Amir Reichman
Number of employees31
Security typeDepository Receipt
Fiscal year-endJun 07
AddressJerusalem Biopark, 2Nd Floor
CityJERUSALEM
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code00000
Phone97289302529
Websitehttps://www.scinai.com/
Ticker SymbolSCNI
IPO dateJun 07, 2007
CEOMr. Amir Reichman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+51.52%
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Mr. Joshua Phillipson
Mr. Joshua Phillipson
Investor Relations
Investor Relations
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, May 28
Updated: Wed, May 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Shareholders
Shareholders
Proportion
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
14.34%
Corporation
9.47%
Individual Investor
8.75%
Investment Advisor
6.93%
Hedge Fund
5.25%
Research Firm
0.02%
Other
55.24%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
32
381.87K
44.77%
+269.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
2023Q2
41
94.79K
37.87%
-787.00
2023Q1
43
111.61K
43.64%
+31.95K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yorkville Advisors Global, LP.
93.27K
10.93%
+93.27K
--
Mar 24, 2025
LCK JNK 1 LLC
80.76K
9.47%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
62.40K
7.32%
--
--
Dec 31, 2024
Armistice Capital LLC
44.80K
5.25%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
4.99%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
3.41%
+29.05K
--
Dec 31, 2024
UBS Financial Services, Inc.
14.93K
1.75%
-8.56K
-36.43%
Mar 31, 2025
Reichman (Amir)
8.08K
0.95%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.57K
0.18%
-86.00
-5.20%
Mar 31, 2025
Ben-Yedidia (Tamar)
1.35K
0.16%
+1.35K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Date
Type
Ratio
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
